logo

Lexicon Pharmaceuticals Inc. (LXRX)



Trade LXRX now with
  Date
  Headline
12/5/2017 2:12:11 AM Lexicon Secures Up To $200 Mln Non-Dilutive Term Loan Financing
11/30/2017 6:25:54 AM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $38 Price Target
11/30/2017 6:25:11 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 2018 Estimate To -1.01 From -1.24
11/30/2017 6:24:45 AM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 2017 Estimate To -1.39 From -1.47
11/8/2017 7:13:49 AM Lexicon Q3 Net Loss $30.7 Mln Or $0.29/Shr Vs Net Loss $36.0 Mln Or $0.35/Shr Prior Year
10/5/2017 9:11:21 PM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Outperform With $38 Down $39 Price Target
9/27/2017 7:01:41 AM Lexicon Pharma Initiates Patient Dosing In A Phase 1 Study Of LX9211
9/13/2017 4:33:24 AM Lexicon Publishes Results Of Phase 3 InTandem3 Study Of Sotagliflozin
9/8/2017 7:03:04 AM Lexicon Reports Positive Pooled Continuous Glucose Monitoring Data From Pivotal Phase 3 InTandem
8/7/2017 9:49:50 AM Wedbush Reiterates Lexicon Pharmaceuticals Inc. (LXRX) At Ourperform With $39 Price Target
8/1/2017 7:23:57 AM Lexicon Pharma Q2 Net Loss $35.1 Mln Or $0.33/shr Vs. Net Loss $38.1 Mln Or $0.37/shr Last Year
7/23/2017 11:21:39 PM One Step Closer To EU Approval...
7/21/2017 7:29:05 AM Lexicon Collaborator Ipsen Gets Positive CHMP Opinion For Xermelo
6/9/2017 7:03:33 AM Lexicon Reports Positive Top-Line Results In Phase 3 In Tandem3 Study For Sotagliflozin In Patients With Type 1 Diabetes
5/11/2017 6:37:01 AM Lexicon Pharma Reports Addl Positive Data For Sotagliflozin In Patients With Type 1 Diabetes
3/7/2017 12:42:44 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 2017 Estimate To -1.66 From -2.16
3/7/2017 12:42:29 PM Wedbush Is Increasing Lexicon Pharmaceuticals Inc. (LXRX) 4Q17 Estimate To -0.45 From -0.50
3/7/2017 12:42:13 PM Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) 3Q17 Estimate To -0.28 From -0.47
3/7/2017 12:41:02 PM Wedbush Is Raising Lexicon Pharmaceuticals Inc. (LXRX) 2Q17 Estimate To -0.47 From -0.58